Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

A drug which it is hoped could help people living with one of the most common types of alopecia has been given approval for use in the NHS in Scotland. Ritlecitinib, provided under the brand name ...

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

The daily pill, called ritlecitinib or litfulo, could help up to 14,000 people in England, says the National Institute for Health and Care Excellence (NICE). Scotland is currently considering ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...